He et al. BMC Cancer 2010, 10:681 http://www.biomedcentral.com/1471-2407/10/681 City, China. 3Department of Radiology, The First Hospital, China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang City, China. 4Department of Medical Oncology, The Oncology Hospital of Liaoning Province in China. NO. 44, Xiaoheyan Road, Dadong District, Shenyang City, China. Authors’ contributions LH conceived of the study, participated in design and prepare the manuscript, YT participated in the design of the study, BJ participated in the design and performed the statistical analysis, MZ participated in the design, PY participated in the design, XH participated in the design, JZ participated in the design, SL participated in the data collection, YG participated in the data collection, YL conceived of the study, participated in design and coordination. All authors read and approved the final manuscript. Competing interests The authors declare that they have no competing interests. Received: 24 March 2010 Accepted: 14 December 2010 Published: 14 December 2010 References 1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216. 2. Lara NPrimo Jr, Redman WMary, Karen Kelly, Edelman JMartin, Williamson KStephen, Crowley JJohn, Gandara RDavid: Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non-Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials. J Clin Oncol 2008, 26:463-467. 3. Chikako Suzuki, Hans Jacobsson, Thomas Hatschek, Torkzad RMichael, Katarina Bodén, Yvonne Eriksson-Alm, Elisabeth Berg, Hirofumi Fujii, Atsushi Kubo, Lennart Blomqvist: Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations. Radiographics 2008, 28:329-344. 4. Karnofsky DA: Meaningful clinical classification of therapeutic responses to anticancer drugs. Clin Pharmacol Ther 1961, 2:709-712. 5. Moertel CG, Hanley JA: The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 1976, 38:388-394. 6. James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P: Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999, 91:523-528. 7. Padhani AR, Ollivier L: The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 2001, 74:983-986. 8. Sirohi B, Ashley S, Norton A, Popat S, Hughes S, Papadopoulos P, Priest K, O’Brien M: Early response to platinum-based first-Line chemotherapy in non-small cell lung cancer may predict survival. J Thorac Oncol 2007, 2:735-740. 9. Therasse P: Measuring the clinical response. What does it mean? Eur J Cancer 2002, 38:1817-1823. 10. Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, Brouchet L, Quoix E, Westeel V, Le Chevalier-T: Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000, 18:2981-2989. 11. Fidias P, Dakhil SR, Lyss AP, Loesch DM, Waterhouse D, Cunneen J, Ye Z, Tai F, Obasaju CK, Schiller JH: Updated report of a phase III study of induction therapy with gemcitabine + carboplatin (GC) followed by either delayed vs immediate second line therapy with docetaxel (D) in advanced non small cell lung cancer (NSCLC) [Abstract]. J Clin Oncol 2006, 24:s18. 12. Victorson D, Soni M, Cella D: Metaanalysis of the correlation between radiographic tumor response and patient-reported outcomes. Cancer 2006, 106:494-504. 13. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S: KRAS wild-type state predicts survival and is Page 10 of 11 associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Annals of Oncology 2008, 19:508-515. 14. Piessevaux H, Buyse M, De Roock W, Prenen H, Schlichting M, Van Cutsem E, Tejpar S: Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Annals of Oncology 2009, 20:1375-1382. 15. Piessevaux H, De Roock W, Van Cutsem E, Tejpar S: Use of tumor size decrease at 6 weeks (w) to predict response (OR), time to progression (TTP), and survival (OS) in chemorefractory metastatic colorectal cancer (cmCRC) treated with cetuximab (CTX) (BOND trial) [abstract]. J Clin Oncol 2008, 26:s15. 16. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007, 25:1753-1759. 17. Marc Buyse, Tomasz Burzykowski, Kevin Carroll, Stefan Michiels, Sargent JDaniel, Miller LLangdon, Elfring LGary, Jean-Pierre Pignon, Pascal Piedbois: Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007, 25:5218-5224. 18. Tang PA, Bentzen SM, Chen EX, Siu LL: Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007, 25:4562-4568. 19. Carroll KJ: Analysis of progression-free survival in oncology trials: some common statistical issues. Pharm Stat 2007, 6:99-113. 20. Shi Q, Sargent DJ: Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. Int J Clin Oncol 2009, 14:102-111. 21. Levin AVictor, Ictech Sandra, Hess RKenneth: Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. BMC Cancer 2007, 7:106. 22. Methy N, Bedenne L, Bonnetain F: Validation of surrogate endpoints in digestive oncology. Bull Cancer 2009, 96:591-595. 23. Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, et al: Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res 2007, 13:S4583-S4588. 24. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P: Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000, 356:373-378. 25. Birchard KR, Hoang JK, Herndon JE Jr, Patz EF Jr: Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer 2009, 115:581-586. 26. Cesano A, Lane SR, Poulin R, Ross G, Fields SZ: Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol 1999, 15:1233-1238. 27. Cesano A, Lane SR, Ross GA, Fields SZ: Stabilization of disease as an indicator of clinical benefit associated with chemotherapy in non-small cell lung cancer patients. Int J Oncol 2000, 17:587-590. 28. Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC: Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol 2003, 16:1102-1108. 29. Esendagli G, Bruderek K, Goldmann T, Busche A, Branscheid D, Vollmer E, Brandau S: Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 2008, 59:32-40. 30. Van den Abbeele AD, Badawi RD: Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002, 38(Suppl 5):60-65. 31. Junker K, Langner K, Klinke F, Bosse U, Thomas M: Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest 2001, 120:1584-1591. 32. Junker K, Thomas M, Schulmann K, Klinke F, Bosse U, Mueller KM: Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment. J Cancer Res Clin Oncol 1997, 123:469-477.